Typhoid fever

Last updated

Typhoid fever
Other namesEnteric fever, slow fever
SalmonellaTyphiFlagellarStain.jpg
Causative agent: Salmonella enterica serological variant Typhi (shown under a microscope with flagellar stain)
Specialty Infectious diseases   OOjs UI icon edit-ltr-progressive.svg
Symptoms Fever that starts low and increases daily, possibly reaching as high as 104.9 °F (40.5 °C) Headache, weakness and fatigue, muscle aches, sweating, dry cough, loss of appetite, weight loss, stomach pain, diarrhea or constipation, rash, swollen stomach (enlarged liver or spleen)
Usual onset1–2 weeks after ingestion
DurationUsually 7–10 days after antibiotic treatment begins. Longer if there are complications or drug resistance.
CausesGastrointestinal infection of Salmonella enterica serotype Typhi
Risk factors Living in or travel to areas where typhoid fever is established; work as a clinical microbiologist handling Salmonella Typhi bacteria; have close contact with someone who is infected or has recently been infected with typhoid fever; drink water polluted by sewage that contains Salmonella Typhi
PreventionPreventable by vaccine. Travelers to regions with higher typhoid prevalence are usually encouraged to get a vaccination before travel.
TreatmentAntibiotics, hydration, surgery in extreme cases. Quarantine to avoid exposing others (not commonly done in modern times).
Prognosis Likely to recover without complications if proper antibiotics administered and diagnosed early. If infecting strain is multi-drug resistant or extensively drug resistant then prognosis more difficult to determine.

Among untreated acute cases, 10% will shed bacteria for three months after initial onset of symptoms, and 2–5% will become chronic typhoid carriers. [1]

Some carriers are diagnosed by positive tissue specimen. Chronic carriers are by definition asymptomatic.

Contents

[1]

Typhoid fever, also known simply as typhoid, is a disease caused by Salmonella enterica serotype Typhi bacteria, also called Salmonella typhi. [2] [3] Symptoms vary from mild to severe, and usually begin six to 30 days after exposure. [4] [5] Often there is a gradual onset of a high fever over several days. [4] This is commonly accompanied by weakness, abdominal pain, constipation, headaches, and mild vomiting. [6] [5] [7] Some people develop a skin rash with rose colored spots. [5] In severe cases, people may experience confusion. [7] Without treatment, symptoms may last weeks or months. [5] Diarrhea may be severe, but is uncommon. [7] Other people may carry it without being affected, but are still contagious. [8] Typhoid fever is a type of enteric fever, along with paratyphoid fever. [2] Salmonella enterica Typhi is believed to infect and replicate only within humans. [9]

Typhoid is caused by the bacterium Salmonella enterica subsp. enterica serovar Typhi growing in the intestines, Peyer's patches, mesenteric lymph nodes, spleen, liver, gallbladder, bone marrow and blood. [5] [7] Typhoid is spread by eating or drinking food or water contaminated with the feces of an infected person. [8] Risk factors include limited access to clean drinking water and poor sanitation. [2] Those who have not yet been exposed to it and ingest contaminated drinking water or food are most at risk for developing symptoms. [7] Only humans can be infected; there are no known animal reservoirs. [8] Salmonella Typhi which causes typhoid fever is different than the other Salmonella bacteria that usually cause salmonellosis, a common type of food poisoning. [10]

Diagnosis is performed by culturing and identifying S. enterica typhi from patient samples or detecting an immune response to the pathogen from blood samples. [5] [2] [11] Recently, new advances in large-scale data collection and analysis have allowed researchers to develop better diagnostics, such as detecting changing abundances of small molecules in the blood that may specifically indicate typhoid fever. [12] Diagnostic tools in regions where typhoid is most prevalent are quite limited in their accuracy and specificity, and the time required for a proper diagnosis, the increasing spread of antibiotic resistance, and the cost of testing are also hardships for under-resourced healthcare systems. [9]

A typhoid vaccine can prevent about 40–90% of cases during the first two years. [13] The vaccine may have some effect for up to seven years. [2] For those at high risk or people traveling to areas where it is common, vaccination is recommended. [8] Other efforts to prevent it include providing clean drinking water, good sanitation, and handwashing. [5] [8] Until an infection is confirmed as cleared, the infected person should not prepare food for others. [5] Typhoid is treated with antibiotics such as azithromycin, fluoroquinolones, or third-generation cephalosporins. [2] Resistance to these antibiotics has been developing, which has made treatment more difficult. [2] [14] [15]

In 2015, 12.5 million new typhoid cases were reported. [16] The disease is most common in India. [2] Children are most commonly affected. [2] [8] Typhoid decreased in the developed world in the 1940s as a result of improved sanitation and the use of antibiotics. [8] Every year about 400 cases are reported in the U.S. and an estimated 6,000 people have typhoid. [7] [17] In 2015, it resulted in about 149,000 deaths worldwide – down from 181,000 in 1990. [18] [19] Without treatment, the risk of death may be as high as 20%. [8] With treatment, it is between 1% and 4%. [2] [8]

Typhus is a different disease, caused by unrelated species of bacteria. [20] Owing to their similar symptoms, they were not recognized as distinct diseases until the 1800s. "Typhoid" means "resembling typhus". [21]

Signs and symptoms

Classically, the progression of untreated typhoid fever has three distinct stages, each lasting about a week. Over the course of these stages, the patient becomes exhausted and emaciated. [22]

Causes

A 1939 conceptual illustration showing various ways that typhoid bacteria can contaminate a water well (center) ForskeligeVeje ad hvilkenBroen kan inficeres medTyfusbaciller.png
A 1939 conceptual illustration showing various ways that typhoid bacteria can contaminate a water well (center)

Bacteria

The Gram-negative bacterium that causes typhoid fever is Salmonella enterica subsp. enterica serovar Typhi. Based on MLST subtyping scheme, the two main sequence types of the S. Typhi are ST1 and ST2, which are widespread globally. [25] Global phylogeographical analysis showed dominance of a haplotype 58 (H58), which probably originated in India during the late 1980s and is now spreading through the world with multi-drug resistance. [26] A more detailed genotyping scheme was reported in 2016 and is now being used widely. This scheme reclassified the nomenclature of H58 to genotype 4.3.1. [27]

Transmission

Unlike other strains of Salmonella , humans are the only known carriers of typhoid. [28] S. enterica subsp. enterica serovar Typhi is spread by the fecal-oral route from people who are infected and from asymptomatic carriers of the bacterium. [28] An asymptomatic human carrier is someone who is still excreting typhoid bacteria in stool a year after the acute stage of the infection. [28]

Pathogenesis of typhoid fever STyphipathogenesisdiagram.jpg
Pathogenesis of typhoid fever

Diagnosis

Diagnosis is made by any blood, bone marrow, or stool cultures and with the Widal test (demonstration of antibodies against Salmonella antigens O-somatic and H-flagellar). In epidemics and less wealthy countries, after excluding malaria, dysentery, or pneumonia, a therapeutic trial time with chloramphenicol is generally undertaken while awaiting the results of the Widal test and blood and stool cultures. [29]

Widal test

Widal test card Widal Test Slide.jpg
Widal test card

The Widal test is used to identify specific antibodies in the serum of people with typhoid by using antigen-antibody interactions. [30]

In this test, the serum is mixed with a dead bacterial suspension of Salmonella with specific antigens. If the patient's serum contains antibodies against those antigens, they get attached to them, forming clumps. If clumping does not occur, the test is negative. The Widal test is time-consuming and prone to significant false positives. It may also be falsely negative in recently infected people. But unlike the Typhidot test, the Widal test quantifies the specimen with titres. [31]

Rapid diagnostic tests

Rapid diagnostic tests such as Tubex, Typhidot, and Test-It have shown moderate diagnostic accuracy. [32]

Typhidot

Typhidot is based on the presence of specific IgM and IgG antibodies to a specific 50Kd OMP antigen. This test is carried out on a cellulose nitrate membrane where a specific S. typhi outer membrane protein is attached as fixed test lines. It separately identifies IgM and IgG antibodies. IgM shows recent infection; IgG signifies remote infection.[ citation needed ]

The sample pad of this kit contains colloidal gold-anti-human IgG or gold-anti-human IgM. If the sample contains IgG and IgM antibodies against those antigens, they will react and turn red. The typhidot test becomes positive within 2–3 days of infection.[ citation needed ]

Two colored bands indicate a positive test. A single control band indicates a negative test. A single first fixed line or no band at all indicates an invalid test. Typhidot's biggest limitation is that it is not quantitative, just positive or negative. [33]

Tubex test

The Tubex test contains two types of particles: brown magnetic particles coated with antigen and blue indicator particles coated with O9 antibody. During the test, if antibodies are present in the serum, they will attach to the brown magnetic particles and settle at the base, while the blue indicator particles remain in the solution, producing a blue color, which means the test is positive.[ citation needed ]

If the serum does not have an antibody in it, the blue particles attach to the brown particles and settle at the bottom, producing a colorless solution, which means the test is negative. [34]

Prevention

Doctor administering a typhoid vaccination at a school in San Augustine County, Texas, 1943 Typhoid inoculation2.jpg
Doctor administering a typhoid vaccination at a school in San Augustine County, Texas, 1943

Sanitation and hygiene are important to prevent typhoid. It can spread only in environments where human feces can come into contact with food or drinking water. Careful food preparation and washing of hands are crucial to prevent typhoid. Industrialization contributed greatly to the elimination of typhoid fever, as it eliminated the public-health hazards associated with having horse manure in public streets, which led to a large number of flies, [35] which are vectors of many pathogens, including Salmonella spp. [36] According to statistics from the U.S. Centers for Disease Control and Prevention, the chlorination of drinking water has led to dramatic decreases in the transmission of typhoid fever. [37]

Vaccination

Two typhoid vaccines are licensed for use for the prevention of typhoid: [13] the live, oral Ty21a vaccine (sold as Vivotif by Crucell Switzerland AG) and the injectable typhoid polysaccharide vaccine (sold as Typhim Vi by Sanofi Pasteur and Typherix by GlaxoSmithKline). Both are efficacious and recommended for travelers to areas where typhoid is endemic. Boosters are recommended every five years for the oral vaccine and every two years for the injectable form. [13] An older, killed whole-cell vaccine is still used in countries where the newer preparations are not available, but this vaccine is no longer recommended for use because it has more side effects (mainly pain and inflammation at the site of the injection). [38]

Vivotif - oral typhoid vaccine of live-attenuated S. enterica Typhi strain Ty21a Vivotif-typhoid-live-oral-vaccine.JPG
Vivotif – oral typhoid vaccine of live-attenuated S. enterica Typhi strain Ty21a

To help decrease rates of typhoid fever in developing nations, the World Health Organization (WHO) endorsed the use of a vaccination program starting in 1999. Vaccination has proven effective at controlling outbreaks in high-incidence areas and is also very cost-effective: prices are normally less than US$1 per dose. Because the price is low, poverty-stricken communities are more willing to take advantage of the vaccinations. [39] Although vaccination programs for typhoid have proven effective, they alone cannot eliminate typhoid fever. [39] Combining vaccines with public-health efforts is the only proven way to control this disease. [39]

Since the 1990s, the WHO has recommended two typhoid fever vaccines. The ViPS vaccine is given by injection, and the Ty21a by capsules. Only people over age two are recommended to be vaccinated with the ViPS vaccine, and it requires a revaccination after 2–3 years, with a 55–72% efficacy. The Ty21a vaccine is recommended for people five and older, lasting 5–7 years with 51–67% efficacy. The two vaccines have proved safe and effective for epidemic disease control in multiple regions. [39]

A version of the vaccine combined with a hepatitis A vaccine is also available. [40]

Results of a phase 3 trial of typhoid conjugate vaccine (TCV) in December 2019 reported 81% fewer cases among children. [41] [42]

Treatment

Oral rehydration therapy

The rediscovery of oral rehydration therapy in the 1960s provided a simple way to prevent many of the deaths of diarrheal diseases in general. [43]

Antibiotics

Where resistance is uncommon, the treatment of choice is a fluoroquinolone such as ciprofloxacin. [44] [45] Otherwise, a third-generation cephalosporin such as ceftriaxone or cefotaxime is the first choice. [46] [47] [48] [49] Cefixime is a suitable oral alternative. [50] [51]

Properly treated, typhoid fever is not fatal in most cases. Antibiotics such as ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, amoxicillin, and ciprofloxacin have been commonly used to treat it. [52] Treatment with antibiotics reduces the case-fatality rate to about 1%. [53]

Without treatment, some patients develop sustained fever, bradycardia, hepatosplenomegaly, abdominal symptoms, and occasionally pneumonia. In white-skinned patients, pink spots, which fade on pressure, appear on the skin of the trunk in up to 20% of cases. In the third week, untreated cases may develop gastrointestinal and cerebral complications, which may prove fatal in 10–20% of cases. The highest case fatality rates are reported in children under 4. Around 2–5% of those who contract typhoid fever become chronic carriers, as bacteria persist in the biliary tract after symptoms have resolved. [54]

Surgery

Surgery is usually indicated if intestinal perforation occurs. One study found a 30-day mortality rate of 9% (8/88), and surgical site infections at 67% (59/88), with the disease burden borne predominantly by low-resource countries. [55]

For surgical treatment, most surgeons prefer simple closure of the perforation with drainage of the peritoneum. Small-bowel resection is indicated for patients with multiple perforations. If antibiotic treatment fails to eradicate the hepatobiliary carriage, the gallbladder should be resected. Cholecystectomy is sometimes successful, especially in patients with gallstones, but is not always successful in eradicating the carrier state because of persisting hepatic infection. [56] [57]

Resistance

As resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, and streptomycin is now common, these agents are no longer used as first–line treatment of typhoid fever. [58] Typhoid resistant to these agents is known as multidrug-resistant typhoid. [59]

Ciprofloxacin resistance is an increasing problem, especially in the Indian subcontinent and Southeast Asia. Many centres are shifting from ciprofloxacin to ceftriaxone as the first line for treating suspected typhoid originating in South America, India, Pakistan, Bangladesh, Thailand, or Vietnam. Also, it has been suggested that azithromycin is better at treating resistant typhoid than both fluoroquinolone drugs and ceftriaxone. [45] Azithromycin can be taken by mouth and is less expensive than ceftriaxone, which is given by injection. [60]

A separate problem exists with laboratory testing for reduced susceptibility to ciprofloxacin; current recommendations are that isolates should be tested simultaneously against ciprofloxacin (CIP) and against nalidixic acid (NAL), that isolates sensitive to both CIP and NAL should be reported as "sensitive to ciprofloxacin", and that isolates sensitive to CIP but not to NAL should be reported as "reduced sensitivity to ciprofloxacin". But an analysis of 271 isolates found that around 18% of isolates with a reduced susceptibility to fluoroquinolones, the class which CIP belongs (MIC 0.125–1.0 mg/L), would not be detected by this method. [61]

Epidemiology

Typhoid fever incidence; most common in Asia, Africa, Central and South America

.mw-parser-output .legend{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .legend-color{display:inline-block;min-width:1.25em;height:1.25em;line-height:1.25;margin:1px 0;text-align:center;border:1px solid black;background-color:transparent;color:black}.mw-parser-output .legend-text{}
Strongly endemic areas
Moderately endemic areas Fievre typhoide.png
Typhoid fever incidence; most common in Asia, Africa, Central and South America
  Strongly endemic areas
  Moderately endemic areas

In 2000, typhoid fever caused an estimated 21.7 million illnesses and 217,000 deaths. [11] It occurs most often in children and young adults between 5 and 19 years old. [62] In 2013, it resulted in about 161,000 deaths – down from 181,000 in 1990. [19] Infants, children, and adolescents in south-central and Southeast Asia have the highest rates of typhoid. [63] Outbreaks are also often reported in sub-Saharan Africa and Southeast Asia. [64] [65] [66] In 2000, more than 90% of morbidity and mortality due to typhoid fever occurred in Asia. [67] In the U.S., about 400 cases occur each year, 75% of which are acquired while traveling internationally. [68] [69]

Before the antibiotic era, the case fatality rate of typhoid fever was 10–20%. Today, with prompt treatment, it is less than 1%, [70] but 3–5% of people who are infected develop a chronic infection in the gall bladder. [71] Since S. enterica subsp. enterica serovar Typhi is human-restricted, these chronic carriers become the crucial reservoir, which can persist for decades for further spread of the disease, further complicating its identification and treatment. [57] Lately, the study of S. enterica subsp. enterica serovar Typhi associated with a large outbreak and a carrier at the genome level provides new insight into the pathogenesis of the pathogen. [72] [73]

In industrialized nations, water sanitation and food handling improvements have reduced the number of typhoid cases. [74] Third world nations have the highest rates. These areas lack access to clean water, proper sanitation systems, and proper health-care facilities. In these areas, such access to basic public-health needs is not expected in the near future. [75]

In 2004–2005 an outbreak in the Democratic Republic of Congo resulted in more than 42,000 cases and 214 deaths. [62] Since November 2016, Pakistan has had an outbreak of extensively drug-resistant (XDR) typhoid fever. [76]

In Europe, a report based on data for 2017 retrieved from The European Surveillance System (TESSy) on the distribution of confirmed typhoid and paratyphoid fever cases found that 22 EU/EEA countries reported a total of 1,098 cases, 90.9% of which were travel-related, mainly acquired during travel to South Asia. [77]

Outbreaks

Map of Typhoid Fever Outbreaks 1989-2018 TyphoidOutbreaksMap.pdf
Map of Typhoid Fever Outbreaks 1989–2018

History

Early descriptions

The plague of Athens, during the Peloponnesian War, was most likely an outbreak of typhoid fever. [82] During the war, Athenians retreated into a walled-in city to escape attack from the Spartans. This massive influx of humans into a concentrated space overwhelmed the water supply and waste infrastructure, likely leading to unsanitary conditions as fresh water became harder to obtain and waste became more difficult to collect and remove beyond the city walls. [82] In 2006, examining the remains for a mass burial site from Athens from around the time of the plague (~430 B.C.) revealed that fragments of DNA similar to modern day S. Typhi DNA were detected, whereas Yersinia pestis (plague), Rickettsia prowazekii (typhus), Mycobacterium tuberculosis , cowpox virus, and Bartonella henselae were not detected in any of the remains tested. [79]

It is possible that the Roman emperor Augustus Caesar had either a liver abscess or typhoid fever, and survived by using ice baths and cold compresses as a means of treatment for his fever. [82] There is a statue of the Greek physician, Antonius Musa, [90] who treated his fever. [91]

Definition and evidence of transmission

The French doctors Pierre-Fidele Bretonneau and Pierre-Charles-Alexandre Louis are credited with describing typhoid fever as a specific disease, unique from typhus. Both doctors performed autopsies on individuals who died in Paris due to fever – and indicated that many had lesions on the Peyer's patches which correlated with distinct symptoms before death. [82] British medics were skeptical of the differentiation between typhoid and typhus because both were endemic to Britain at that time. However, in France only typhoid was present circulating in the population. [82] Pierre-Charlles-Alexandre Louis also performed case studies and statistical analysis to demonstrate that typhoid was contagious – and that persons who already had the disease seemed to be protected. [82] Afterward, several American doctors confirmed these findings, and then Sir William Jenner convinced any remaining skeptics that typhoid is a specific disease recognizable by lesions in the Peyer's patches by examining sixty-six autopsies from fever patients and concluding that the symptoms of headaches, diarrhea, rash spots, and abdominal pain were present only in patients who were found to have intestinal lesions after death; these observations solidified the association of the disease with the intestinal tract and gave the first clue to the route of transmission. [82]

In 1847 William Budd learned of an epidemic of typhoid fever in Clifton, and identified that all 13 of 34 residents who had contracted the disease drew their drinking water from the same well. [82] Notably, this observation was two years prior to John Snow first publishing an early version of his theory that contaminated water was the central conduit for transmitting cholera. Budd later became health officer of Bristol and ensured a clean water supply, and documented further evidence of typhoid as a water-borne illness throughout his career. [82]

Cause

Polish scientist Tadeusz Browicz described a short bacillus in the organs and feces of typhoid victims in 1874. [92] Browicz was able to isolate and grow the bacilli but did not go as far as to insinuate or prove that they caused the disease. [82]

In April 1880, three months prior to Eberth's publication, Edwin Klebs described short and filamentous bacilli in the Peyer's patches in typhoid victims. [93] The bacterium's role in disease was speculated but not confirmed. [82]

In 1880, Karl Joseph Eberth described a bacillus that he suspected was the cause of typhoid. [94] [95] [96] Eberth is given credit for discovering the bacterium definitively by successfully isolating the same bacterium from 18 of 40 typhoid victims and failing to discover the bacterium present in any "control" victims of other diseases. [82] In 1884, pathologist Georg Theodor August Gaffky (1850–1918) confirmed Eberth's findings. [97] Gaffky isolated the same bacterium as Eberth from the spleen of a typhoid victim, and was able to grow the bacterium on solid media. [82] The organism was given names such as Eberth's bacillus, Eberthella Typhi, and Gaffky-Eberth bacillus. [82] Today, the bacillus that causes typhoid fever goes by the scientific name Salmonella enterica serovar Typhi. [98]

Chlorination of water

Most developed countries had declining rates of typhoid fever throughout the first half of the 20th century due to vaccinations and advances in public sanitation and hygiene. In 1893 attempts were made to chlorinate the water supply in Hamburg, Germany and in 1897 Maidstone, England, was the first town to have its entire water supply chlorinated. [99] In 1905, following an outbreak of typhoid fever, the City of Lincoln, England, instituted permanent water chlorination. [100] The first permanent disinfection of drinking water in the US was made in 1908 to the Jersey City, New Jersey, water supply. Credit for the decision to build the chlorination system has been given to John L. Leal. [101] The chlorination facility was designed by George W. Fuller. [102]

Outbreaks in traveling military groups led to the creation of the Lyster bag in 1915: a bag with a faucet which can be hung from a tree or pole, filled with water, and comes with a chlorination tablet to drop into the water. [82] The Lyster bag was essential for the survival of American soldiers in the Vietnam War. [82]

Direct transmission and carriers

Mary Mallon ("Typhoid Mary") in a hospital bed (foreground): She was forcibly quarantined as a carrier of typhoid fever in 1907 for three years and then again from 1915 until her death in 1938. Mary Mallon in hospital.jpg
Mary Mallon ("Typhoid Mary") in a hospital bed (foreground): She was forcibly quarantined as a carrier of typhoid fever in 1907 for three years and then again from 1915 until her death in 1938.

There were several occurrences of milk delivery men spreading typhoid fever throughout the communities they served. Although typhoid is not spread through milk itself, there were several examples of milk distributors in many locations watering their milk down with contaminated water, or cleaning the glass bottles the milk was placed in with contaminated water. [82] [85] Boston had two such cases around the turn of the 20th century. [85] In 1899 there were 24 cases of typhoid traced to a single milkman, whose wife had died of typhoid fever a week before the outbreak. [85] In 1908, J.J. Fallon, who was also a milkman, died of typhoid fever. [85] Following his death and confirmation of the typhoid fever diagnosis, the city conducted an investigation of typhoid symptoms and cases along his route and found evidence of a significant outbreak. A month after the outbreak was first reported, the Boston Globe published a short statement declaring the outbreak over, stating "[a]t Jamaica Plain there is a slight increase, the total being 272 cases. Throughout the city there is a total of 348 cases." [85] There was at least one death reported during this outbreak: Mrs. Sophia S. Engstrom, aged 46. [85] Typhoid continued to ravage the Jamaica Plain neighborhood in particular throughout 1908, and several more people were reported dead due to typhoid fever, although these cases were not explicitly linked to the outbreak. [85] The Jamaica Plain neighborhood at that time was home to many working-class and poor immigrants, mostly from Ireland. [103]

The most notorious carrier of typhoid fever, but by no means the most destructive, was Mary Mallon, known as Typhoid Mary. [104] [87] Although other cases of human-to-human spread of typhoid were known at the time, the concept of an asymptomatic carrier, who was able to transmit disease, had only been hypothesized and not yet identified or proven. [82] Mary Mallon became the first known example of an asymptomatic carrier of an infectious disease, making typhoid fever the first known disease being transmissible through asymptomatic hosts. [82] The cases and deaths caused by Mallon were mainly upper-class families in New York City. [82] At the time of Mallon's tenure as a personal cook for upper-class families, New York City reported 3,000 to 4,500 cases of typhoid fever annually. [82] In the summer of 1906 two daughters of a wealthy family and maids working in their home became ill with typhoid fever. [82] After investigating their home water sources and ruling out water contamination, the family hired civil engineer George Soper to conduct an investigation of the possible source of typhoid fever in the home. [82] Soper described himself as an "epidemic fighter". [82] His investigation ruled out many sources of food, and led him to question if the cook the family hired just prior to their household outbreak, Mallon, was the source. [82] Since she had already left and begun employment elsewhere, he proceeded to track her down in order to obtain a stool sample. [82] When he was able to finally meet Mallon in person he described her by saying "Mary had a good figure and might have been called athletic had she not been a little too heavy." [86] In recounts of Soper's pursuit of Mallon, his only remorse appears to be that he was not given enough credit for his relentless pursuit and publication of her personal identifying information, stating that the media "rob[s] me of whatever credit belongs to the discovery of the first typhoid fever carrier to be found in America." [86] Ultimately, 51 cases and 3 deaths were suspected to be caused by Mallon. [105] [87]

In 1924 the city of Portland, Oregon, experienced an outbreak of typhoid fever, consisting of 26 cases and 5 deaths, all deaths due to intestinal hemorrhage. [106] All cases were concluded to be due to a single milk farm worker, who was shedding large amounts of the typhoid pathogen in his urine. [106] Misidentification of the disease, due to inaccurate Widal test results, delayed identification of the carrier and proper treatment. [106] Ultimately, it took four samplings of different secretions from all of the dairy workers in order to successfully identify the carrier. [106] Upon discovery, the dairy worker was forcibly quarantined for seven weeks, and regular samples were taken, most of the time the stool samples yielding no typhoid and often the urine yielding the pathogen. [106] The carrier was reported as being 72 years old and appearing in excellent health with no symptoms. [106] Pharmaceutical treatment decreased the amount of bacteria secreted, however, the infection was never fully cleared from the urine, and the carrier was released "under orders never again to engage in the handling of foods for human consumption." [106] At the time of release, the authors noted "for more than fifty years he has earned his living chiefly by milking cows and knows little of other forms of labor, it must be expected that the closest surveillance will be necessary to make certain that he does not again engage in this occupation." [106]

Overall, in the early 20th century the medical profession began to identify carriers of the disease, and evidence of transmission independent of water contamination. [82] In a 1933 American Medical Association publication, physicians' treatment of asymptomatic carriers is best summarized by the opening line "Carriers of typhoid bacilli are a menace". [107] Within the same publication, the first official estimate of typhoid carriers is given: 2–5% of all typhoid patients, and distinguished between temporary carriers and chronic carriers. [107] The authors further estimate that there are four to five chronic female carriers to every one male carrier, although offered no data to explain this assertion of a gender difference in the rate of typhoid carriers. [107] As far as treatment, the authors suggest: "When recognized, carriers must be instructed as to the disposal of excreta as well as to the importance of personal cleanliness. They should be forbidden to handle food or drink intended for others, and their movements and whereabouts must be reported to the public health officers". [107]

New Typhoid carrier cases reported in L.A. County between 2006 and 2016 Typhoid LAcounty 2016.jpg
New Typhoid carrier cases reported in L.A. County between 2006 and 2016

Today, typhoid carriers exist all over the world, but the highest incidence of asymptomatic infection is likely to occur in South/Southeast Asian and Sub-Saharan countries. [1] [108] The Los Angeles County department of public health tracks typhoid carriers and reports the number of carriers identified within the county yearly; between 2006 and 2016 0–4 new cases of typhoid carriers were identified per year. [1] Cases of typhoid fever must be reported within one working day from identification. As of 2018, chronic typhoid carriers must sign a "Carrier Agreement" and are required to test for typhoid shedding twice yearly, ideally every 6 months. [109] Carriers may be released from their agreements upon fulfilling "release" requirements, based on completion of a personalized treatment plan designed with medical professionals. [109] Fecal or gallbladder carrier release requirements: 6 consecutive negative feces and urine specimens submitted at 1-month or greater intervals beginning at least 7 days after completion of therapy. [109] Urinary or kidney carrier release requirements: 6 consecutive negative urine specimens submitted at 1-month or greater intervals beginning at least 7 days after completion of therapy. [109]

Due to the nature of asymptomatic cases, many questions remain about how individuals are able to tolerate infection for long periods of time, how to identify such cases, and efficient options for treatment. Researchers are currently working to understand asymptomatic infection with Salmonella species by studying infections in laboratory animals, which will ultimately lead to improved prevention and treatment options for typhoid carriers. In 2002, John Gunn described the ability of Salmonella sp. to form biofilms on gallstones in mice, providing a model for studying carriage in the gallbladder. [110] Denise Monack and Stanley Falkow described a mouse model of asymptomatic intestinal and systemic infection in 2004, and Monack went on to demonstrate that a sub-population of superspreaders are responsible for the majority of transmission to new hosts, following the 80/20 rule of disease transmission, and that the intestinal microbiota likely plays a role in transmission. [111] [112] Monack's mouse model allows long-term carriage of Salmonella in mesenteric lymph nodes, spleen and liver. [111]

Vaccine development

Almroth Edward Wright developed the first effective typhoid vaccine. Almroth Wright c1900.jpg
Almroth Edward Wright developed the first effective typhoid vaccine.

British bacteriologist Almroth Edward Wright first developed an effective typhoid vaccine at the Army Medical School in Netley, Hampshire. It was introduced in 1896 and used successfully by the British during the Second Boer War in South Africa. [113] At that time, typhoid often killed more soldiers at war than were lost due to enemy combat. Wright further developed his vaccine at a newly opened research department at St Mary's Hospital Medical School in London from 1902, where he established a method for measuring protective substances (opsonin) in human blood. [114] Wright's version of the typhoid vaccine was produced by growing the bacterium at body temperature in broth, then heating the bacteria to 60 °C to "heat inactivate" the pathogen, killing it, while keeping the surface antigens intact. The heat-killed bacteria was then injected into a patient. [82] To show evidence of the vaccine's efficacy, Wright then collected serum samples from patients several weeks post-vaccination, and tested their serum's ability to agglutinate live typhoid bacteria. A "positive" result was represented by clumping of bacteria, indicating that the body was producing anti-serum (now called antibodies) against the pathogen. [82]

Citing the example of the Second Boer War, during which many soldiers died from easily preventable diseases, Wright convinced the British Army that 10 million vaccine doses should be produced for the troops being sent to the Western Front, thereby saving up to half a million lives during World War I. [115] The British Army was the only combatant at the outbreak of the war to have its troops fully immunized against the bacterium. For the first time, their casualties due to combat exceeded those from disease. [116]

In 1909, Frederick F. Russell, a U.S. Army physician, adopted Wright's typhoid vaccine for use with the Army, and two years later, his vaccination program became the first in which an entire army was immunized. It eliminated typhoid as a significant cause of morbidity and mortality in the U.S. military. [117] Typhoid vaccination for members of the American military became mandatory in 1911. [82] Before the vaccine, the rate of typhoid fever in the military was 14,000 or greater per 100,000 soldiers. By World War I, the rate of typhoid in American soldiers was 37 per 100,000. [82]

During the second world war, the United States army authorized the use of a trivalent vaccine – containing heat-inactivated Typhoid, Paratyphi A and Paratyphi B pathogens. [82]

In 1934, discovery of the Vi capsular antigen by Arthur Felix and Miss S. R. Margaret Pitt enabled development of the safer Vi Antigen vaccine – which is widely in use today. [118] Arthur Felix and Margaret Pitt also isolated the strain Ty2, which became the parent strain of Ty21a, the strain used as a live-attenuated vaccine for typhoid fever today. [119]

Antibiotics and resistance

Chloramphenicol was isolated from Streptomyces by David Gotlieb during the 1940s. [82] In 1948 American army doctors tested its efficacy in treating typhoid patients in Kuala Lumpur, Malaysia. [82] Individuals who received a full course of treatment cleared the infection, whereas patients given a lower dose had a relapse. [82] Asymptomatic carriers continued to shed bacilli despite chloramphenicol treatment – only ill patients were improved with chloramphenicol. [82] Resistance to chloramphenicol became frequent in Southeast Asia by the 1950s, and today chloramphenicol is only used as a last resort due to the high prevalence of resistance. [82]

Terminology

The disease has been referred to by various names, often associated with symptoms, such as gastric fever, enteric fever, abdominal typhus, infantile remittant fever, slow fever, nervous fever, pythogenic fever, [120] drain fever, and low fever. [121]

Society and culture

Notable people

Related Research Articles

<i>Salmonella</i> Genus of bacteria

Salmonella is a genus of rod-shaped (bacillus) gram-negative bacteria of the family Enterobacteriaceae. The two known species of Salmonella are Salmonella enterica and Salmonella bongori. S. enterica is the type species and is further divided into six subspecies that include over 2,650 serotypes. Salmonella was named after Daniel Elmer Salmon (1850–1914), an American veterinary surgeon.

<span class="mw-page-title-main">Psittacosis</span> Infectious disease in humans

Psittacosis—also known as parrot fever, and ornithosis—is a zoonotic infectious disease in humans caused by a bacterium called Chlamydia psittaci and contracted from infected parrots, such as macaws, cockatiels, and budgerigars, and from pigeons, sparrows, ducks, hens, gulls and many other species of birds. The incidence of infection in canaries and finches is believed to be lower than in psittacine birds.

<i>Salmonella enterica</i> Species of bacterium

Salmonella enterica is a rod-shaped, flagellate, facultative anaerobic, Gram-negative bacterium and a species of the genus Salmonella. It is divided into six subspecies, arizonae (IIIa), diarizonae (IIIb), houtenae (IV), salamae (II), indica (VI), and enterica (I). A number of its serovars are serious human pathogens; many of them are serovars of Salmonella enterica subsp. enterica.

<span class="mw-page-title-main">Leptospirosis</span> Blood infection caused by bacteria

Leptospirosis is a blood infection caused by the bacteria Leptospira that can infect humans, dogs, rodents and many other wild and domesticated animals. Signs and symptoms can range from none to mild to severe. Weil's disease, the acute, severe form of leptospirosis, causes the infected individual to become jaundiced, develop kidney failure, and bleed. Bleeding from the lungs associated with leptospirosis is known as severe pulmonary haemorrhage syndrome.

<span class="mw-page-title-main">Asymptomatic carrier</span> Organism which has become infected with a pathogen but displays no symptoms

An asymptomatic carrier is a person or other organism that has become infected with a pathogen, but shows no signs or symptoms.

<span class="mw-page-title-main">Gastroenteritis</span> Inflammation of the stomach and small intestine

Gastroenteritis, also known as infectious diarrhea, is an inflammation of the gastrointestinal tract including the stomach and intestine. Symptoms may include diarrhea, vomiting, and abdominal pain. Fever, lack of energy, and dehydration may also occur. This typically lasts less than two weeks. Although it is not related to influenza, in the U.S. and U.K., it is sometimes called the "stomach flu".

<span class="mw-page-title-main">Salmonellosis</span> Infection caused by Salmonella bacteria

Salmonellosis is a symptomatic infection caused by bacteria of the Salmonella type. It is the most common disease to be known as food poisoning, these are defined as diseases, usually either infectious or toxic in nature, caused by agents that enter the body through the ingestion of food. In humans, the most common symptoms are diarrhea, fever, abdominal cramps, and vomiting. Symptoms typically occur between 12 hours and 36 hours after exposure, and last from two to seven days. Occasionally more significant disease can result in dehydration. The old, young, and others with a weakened immune system are more likely to develop severe disease. Specific types of Salmonella can result in typhoid fever or paratyphoid fever. Typhoid fever and paratyphoid fever are specific types of salmonellosis, known collectively as enteric fever, and are, respectively, caused by salmonella typhi and paratyphi bacteria, which are only found in humans. Most commonly, salmonellosis cases arise from salmonella bacteria from animals, and chicken is a major source for these infections.

Enteric fever is a medical term encompassing two types of salmonellosis, which, specifically, are typhoid fever and paratyphoid fever. Enteric fever is a potentially life-threatening acute febrile systemic infection and is diagnosed by isolating a pathogen on culture. Typhoid fever is caused by the Salmonella enterica bacteria, serotype typhi, while paratyphoid fever is caused by the Salmonella enterica bacteria, serotype paratyphi A, B, or C. These Salmonella enterica bacteria serovars that cause enteric fever only have human hosts, as opposed to other types of salmonellosis-causing Salmonella bacteria which often have animal reservoirs.

<span class="mw-page-title-main">Paratyphoid fever</span> Bacterial infection caused by one of the three types of Salmonella enterica

Paratyphoid fever, also known simply as paratyphoid, is a bacterial infection caused by one of three types of Salmonella enterica. Symptoms usually begin 6–30 days after exposure and are the same as those of typhoid fever. Often, a gradual onset of a high fever occurs over several days. Weakness, loss of appetite, and headaches also commonly occur. Some people develop a skin rash with rose-colored spots. Without treatment, symptoms may last weeks or months. Other people may carry the bacteria without being affected; however, they are still able to spread the disease to others. Typhoid and paratyphoid are of similar severity. Paratyphoid and typhoid fever are types of enteric fever.

<span class="mw-page-title-main">Subclinical infection</span> Nearly or completely asymptomatic infection

A subclinical infection—sometimes called a preinfection or inapparent infection—is an infection by a pathogen that causes few or no signs or symptoms of infection in the host. Subclinical infections can occur in both humans and animals. Depending on the pathogen, which can be a virus or intestinal parasite, the host may be infectious and able to transmit the pathogen without ever developing symptoms; such a host is called an asymptomatic carrier. Many pathogens, including HIV, typhoid fever, and coronaviruses such as COVID-19 spread in their host populations through subclinical infection.

The Vi capsular polysaccharide vaccine is a typhoid vaccine recommended by the World Health Organization for the prevention of typhoid. The vaccine was first licensed in the US in 1994 and is made from the purified Vi capsular polysaccharide from the Ty2 Salmonella Typhi strain; it is a subunit vaccine.

<span class="mw-page-title-main">Ty21a</span> Typhoid vaccine

Ty21a is a live attenuated bacterial vaccine that protects against typhoid. First licensed in Europe in 1983 and in the United States in 1989, it is an orally administered, live-attenuated Ty2 strain of S. Typhi in which multiple genes, including the genes responsible for the production of Vi, have been deleted so as to render it harmless but nevertheless immunogenic. It is one of the three typhoid vaccines currently recommended by the World Health Organization.

<span class="mw-page-title-main">Typhus</span> Group of infectious diseases

Typhus, also known as typhus fever, is a group of infectious diseases that include epidemic typhus, scrub typhus, and murine typhus. Common symptoms include fever, headache, and a rash. Typically these begin one to two weeks after exposure.

<i>Salmonella enterica <span style="font-style:normal;">subsp.</span> enterica</i> Subspecies of bacterium

Salmonella enterica subsp. enterica is a subspecies of Salmonella enterica, the rod-shaped, flagellated, aerobic, Gram-negative bacterium. Many of the pathogenic serovars of the S. enterica species are in this subspecies, including that responsible for typhoid.

<span class="mw-page-title-main">Superspreading event</span> Event in which 3 or more people attend and an infectious disease is spread much more than usual

A superspreading event (SSEV) is an event in which an infectious disease is spread much more than usual, while an unusually contagious organism infected with a disease is known as a superspreader. In the context of a human-borne illness, a superspreader is an individual who is more likely to infect others, compared with a typical infected person. Such superspreaders are of particular concern in epidemiology.

<span class="mw-page-title-main">Edward Thomas Ryan</span> American microbiologist

Edward Thomas Ryan is an American microbiologist, immunologist, and physician at Harvard University and Massachusetts General Hospital. Ryan served as president of the American Society of Tropical Medicine and Hygiene from 2009 to 2010. Ryan is Professor of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health, Professor of Medicine at Harvard Medical School, and Director of Global Infectious Diseases at the Massachusetts General Hospital. Ryan's research and clinical focus has been on infectious diseases associated with residing in, immigrating from, or traveling through resource-limited areas. Ryan is a Fellow of the American Society of Microbiology, the American Society of Tropical Medicine and Hygiene, the American College of Physicians, and the Infectious Diseases Society of America.

<span class="mw-page-title-main">Cocoliztli epidemics</span> 16th century epidemics in New Spain

The Cocoliztli Epidemic or the Great Pestilence was an outbreak of a mysterious illness characterized by high fevers and bleeding which caused 5–15 million deaths in New Spain during the 16th century. The Aztec people called it cocoliztli, Nahuatl for pestilence. It ravaged the Mexican highlands in epidemic proportions, resulting in the demographic collapse of some Indigenous populations.

<span class="mw-page-title-main">History of typhoid fever</span>

In 2000, typhoid fever caused an estimated 21.7 million illnesses and 217,000 deaths. It occurs most often in children and young adults between 5 and 19 years old. In 2013, it resulted in about 161,000 deaths – down from 181,000 in 1990. Infants, children, and adolescents in south-central and Southeast Asia experience the greatest burden of illness. Outbreaks of typhoid fever are also frequently reported from sub-Saharan Africa and countries in Southeast Asia. In the United States, about 400 cases occur each year, and 75% of these are acquired while traveling internationally.

Melita Alison Gordon is a gastroenterologist who works on invasive gut pathogens and tropical gastrointestinal disease. She leads the Malawi Liverpool Wellcome Trust Salmonella and Enterics Group. Gordon was awarded the British Society of Gastroenterology Sir Francis Avery Jones Research Medal in 2011.

<span class="mw-page-title-main">John Crump</span> New Zealand-born infectious diseases physician, microbiologist, epidemiologist

John Andrew Crump MB ChB, MD, DTM&H, FRACP, FRCPA, FRCP is a New Zealand-born infectious diseases physician, medical microbiologist, and epidemiologist. He is Professor of Medicine, Pathology, and Global Health at the University of Otago and an adjunct professor of medicine, Pathology, and Global Health at Duke University. He served as inaugural co-director of the Otago Global Health Institute, one of the university's research centres. His primary research interest is fever in the tropics, focusing on invasive bacterial diseases and bacterial zoonoses.

References

  1. 1 2 3 4 5 "TYPHOID FEVER, ACUTE AND CARRIER" (PDF). Acute Communicable Disease Control: 2016 Annual Morbidity Report. 2016. p. 133 via Los Angeles County Department of Public Health.
  2. 1 2 3 4 5 6 7 8 9 10 Wain J, Hendriksen RS, Mikoleit ML, Keddy KH, Ochiai RL (March 2015). "Typhoid fever". Lancet. 385 (9973): 1136–45. doi:10.1016/s0140-6736(13)62708-7. PMID   25458731. S2CID   2409150.
  3. Mathur R, Oh H, Zhang D, Park SG, Seo J, Koblansky A, et al. (October 2012). "A Mouse Model of Salmonella Typhi Infection". Cell. 151 (3): 590–602. doi:10.1016/j.cell.2012.08.042. ISSN   0092-8674. PMC   3500584 . PMID   23101627.
  4. 1 2 Newton AE (2014). "3 Infectious Diseases Related To Travel". CDC health information for international travel 2014: the yellow book. Oup USA. ISBN   978-0-19-994849-9. Archived from the original on 2015-07-02.
  5. 1 2 3 4 5 6 7 8 "Typhoid Fever". cdc.gov. May 14, 2013. Archived from the original on 6 June 2016. Retrieved 28 March 2015.
  6. "Typhoid". www.who.int. Retrieved 2024-05-18.
  7. 1 2 3 4 5 6 "Typhoid Fever". cdc.gov. May 14, 2013. Archived from the original on 2 April 2015. Retrieved 28 March 2015.
  8. 1 2 3 4 5 6 7 8 9 "Typhoid vaccines: WHO position paper" (PDF). Relevé Épidémiologique Hebdomadaire. 83 (6): 49–59. February 2008. PMID   18260212. Archived from the original (PDF) on April 2, 2015.
  9. 1 2 Pitzer VE, Meiring J, Martineau FP, Watson CH, Kang G, Basnyat B, et al. (October 2019). "The Invisible Burden: Diagnosing and Combatting Typhoid Fever in Asia and Africa". Clinical Infectious Diseases. 69 (Suppl 5): S395–S401. doi:10.1093/cid/ciz611. PMC   6792124 . PMID   31612938.
  10. "Typhoid Fever: Causes, Symptoms & Treatment".
  11. 1 2 Crump JA, Mintz ED (January 2010). "Global trends in typhoid and paratyphoid Fever". Clinical Infectious Diseases. 50 (2): 241–6. doi:10.1086/649541. PMC   2798017 . PMID   20014951.
  12. Näsström E, Parry CM, Thieu NT, Maude RR, de Jong HK, Fukushima M, et al. (2017). Reproducible diagnostic metabolites in plasma from typhoid fever patients in Asia and Africa. Umeå universitet, Kemiska institutionen. OCLC   1234663430.
  13. 1 2 3 Milligan R, Paul M, Richardson M, Neuberger A (May 2018). "Vaccines for preventing typhoid fever". The Cochrane Database of Systematic Reviews. 2018 (5): CD001261. doi:10.1002/14651858.CD001261.pub4. PMC   6494485 . PMID   29851031.
  14. Chatham-Stephens K, Medalla F, Hughes M, Appiah GD, Aubert RD, Caidi H, et al. (January 2019). "Emergence of Extensively Drug-Resistant Salmonella Typhi Infections Among Travelers to or from Pakistan – United States, 2016–2018". MMWR. Morbidity and Mortality Weekly Report. 68 (1): 11–13. doi:10.15585/mmwr.mm6801a3. PMC   6342547 . PMID   30629573.
  15. Kuehn R, Stoesser N, Eyre D, Darton TC, Basnyat B, Parry CM (24 November 2022). "Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins". Cochrane Database of Systematic Reviews. 2022 (11): CD010452. doi:10.1002/14651858.CD010452.pub2. PMC   9686137 . PMID   36420914.
  16. Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. (GBD 2015 Disease and Injury Incidence and Prevalence Collaborators) (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC   5055577 . PMID   27733282.
  17. Jackson BR, Iqbal S, Mahon B (March 2015). "Updated recommendations for the use of typhoid vaccine—Advisory Committee on Immunization Practices, United States, 2015". MMWR. Morbidity and Mortality Weekly Report. 64 (11): 305–8. PMC   4584884 . PMID   25811680.
  18. Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. (GBD 2015 Mortality and Causes of Death Collaborators) (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC   5388903 . PMID   27733281.
  19. 1 2 Abubakar II, Tillmann T, Banerjee A, et al. (GBD 2013 Mortality and Causes of Death Collaborators) (January 2015). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 385 (9963): 117–71. doi:10.1016/S0140-6736(14)61682-2. PMC   4340604 . PMID   25530442.
  20. Cunha BA (March 2004). "Osler on typhoid fever: differentiating typhoid from typhus and malaria". Infectious Disease Clinics of North America. 18 (1): 111–25. doi:10.1016/S0891-5520(03)00094-1. PMID   15081508.
  21. Evans AS, Brachman PS (2013). Bacterial Infections of Humans: Epidemiology and Control. Springer. p. 839. ISBN   978-1-4615-5327-4.
  22. "Typhoid". Merriam Webster Dictionary. Archived from the original on 2013-07-02. Retrieved 2013-06-24.
  23. Kumar P, Kumar R (March 2017). "Enteric Fever". Indian Journal of Pediatrics. 84 (3): 227–230. doi:10.1007/s12098-016-2246-4. PMID   27796818. S2CID   3825885.
  24. "Typhoid fever: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 2020-04-21.
  25. Yap KP, Ho WS, Gan HM, Chai LC, Thong KL (2016). "Global MLST of Salmonella Typhi Revisited in Post-genomic Era: Genetic Conservation, Population Structure, and Comparative Genomics of Rare Sequence Types". Frontiers in Microbiology. 7: 270. doi: 10.3389/fmicb.2016.00270 . PMC   4774407 . PMID   26973639.
  26. Wong VK, Baker S, Pickard DJ, Parkhill J, Page AJ, Feasey NA, et al. (June 2015). "Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events". Nature Genetics. 47 (6): 632–9. doi:10.1038/ng.3281. PMC   4921243 . PMID   25961941.
  27. Wong VK, Baker S, Connor TR, Pickard D, Page AJ, Dave J, et al. (October 2016). "An extended genotyping framework for Salmonella enterica serovar Typhi, the cause of human typhoid". Nature Communications. 7 (1): 12827. Bibcode:2016NatCo...712827W. doi: 10.1038/ncomms12827 . PMC   5059462 . PMID   27703135.
  28. 1 2 3 Eng SK, Pusparajah P, Ab Mutalib NS, Ser HL, Chan KG, Lee LH (June 2015). "Salmonella:A review on pathogenesis, epidemiology and antibiotic resistance". Frontiers in Life Science. 8 (3): 284–293. doi: 10.1080/21553769.2015.1051243 .
  29. Ryan KJ, Ray CG, eds. (2004). Sherris Medical Microbiology (4th ed.). McGraw Hill. ISBN   978-0-8385-8529-0.
  30. Mawazo A, Bwire GM, Matee MI (2019-06-05). "Performance of Widal test and stool culture in the diagnosis of typhoid fever among suspected patients in Dar es Salaam, Tanzania". BMC Research Notes. 12 (1): 316. doi: 10.1186/s13104-019-4340-y . ISSN   1756-0500. PMC   6551910 . PMID   31167646.
  31. Feasey NA, Gordon MA (2014). "Salmonella Infections". In Farrar J, Hotez P, Junghanss T, Kang G, Lalloo D, White NJ (eds.). Manson's Tropical Infectious Diseases (23rd ed.). Saunders Ltd. pp. 337–348.e2. doi:10.1016/B978-0-7020-5101-2.00026-1. ISBN   978-0-7020-5101-2.
  32. Wijedoru L, Mallett S, Parry CM, et al. (Cochrane Infectious Diseases Group) (May 2017). "Rapid diagnostic tests for typhoid and paratyphoid (enteric) fever". The Cochrane Database of Systematic Reviews. 2017 (5): CD008892. doi:10.1002/14651858.CD008892.pub2. PMC   5458098 . PMID   28545155.
  33. Lim PL, Tam FC, Cheong YM, Jegathesan M (August 1998). "One-step 2-minute test to detect typhoid-specific antibodies based on particle separation in tubes". Journal of Clinical Microbiology. 36 (8): 2271–8. doi:10.1128/JCM.36.8.2271-2278.1998. PMC   105030 . PMID   9666004.
  34. "TYPHIDOT Rapid IgG/IgM (Combo)" (PDF). Reszon Diagnostics International. Retrieved 14 November 2019.
  35. "The Great Horse Manure Crisis of 1894". Archived from the original on 2015-05-25.
  36. Cirillo VJ (2006). ""Winged sponges": houseflies as carriers of typhoid fever in 19th- and early 20th-century military camps". Perspectives in Biology and Medicine. 49 (1): 52–63. doi:10.1353/pbm.2006.0005. PMID   16489276. S2CID   41428479.
  37. "History of Drinking Water Treatment | Drinking Water | Healthy Water | CDC". www.cdc.gov. 2018-10-10. Retrieved 2020-04-21.
  38. Marathe SA, Lahiri A, Negi VD, Chakravortty D (2012). "Typhoid fever & vaccine development: a partially answered question". The Indian Journal of Medical Research. 135 (2): 161–9. PMC   3336846 . PMID   22446857.
  39. 1 2 3 4 Date KA, Bentsi-Enchill A, Marks F, Fox K (June 2015). "Typhoid fever vaccination strategies". Vaccine. 33 (Suppl 3): C55-61. doi:10.1016/j.vaccine.2015.04.028. PMC   10644681 . PMID   25902360.
  40. "Vivaxim Solution for injection". NPS MedicineWise. Archived from the original on 1 October 2015. Retrieved 10 April 2017.
  41. Gallagher J (4 December 2019). "Typhoid vaccine 'works fantastically well'". BBC News. Retrieved 17 January 2020.
  42. Shakya M, Colin-Jones R, Theiss-Nyland K, Voysey M, Pant D, Smith N, et al. (December 2019). "Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal". The New England Journal of Medicine. 381 (23): 2209–2218. doi: 10.1056/NEJMoa1905047 . PMC   6785806 . PMID   31800986.
  43. "UpToDate". www.uptodate.com. Retrieved 2020-04-21.
  44. Parry CM, Beeching NJ (June 2009). "Treatment of enteric fever". BMJ. 338: b1159. doi:10.1136/bmj.b1159. PMID   19493937. S2CID   3264721.
  45. 1 2 Effa EE, Lassi ZS, Critchley JA, Garner P, Sinclair D, Olliaro PL, et al. (October 2011). "Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)". The Cochrane Database of Systematic Reviews. 2011 (10): CD004530. doi:10.1002/14651858.CD004530.pub4. PMC   6532575 . PMID   21975746.
  46. Soe GB, Overturf GD (1987). "Treatment of typhoid fever and other systemic salmonelloses with cefotaxime, ceftriaxone, cefoperazone, and other newer cephalosporins". Reviews of Infectious Diseases. 9 (4): 719–36. doi:10.1093/clinids/9.4.719. JSTOR   4454162. PMID   3125577.
  47. Wallace MR, Yousif AA, Mahroos GA, Mapes T, Threlfall EJ, Rowe B, et al. (December 1993). "Ciprofloxacin versus ceftriaxone in the treatment of multiresistant typhoid fever". European Journal of Clinical Microbiology & Infectious Diseases. 12 (12): 907–10. doi:10.1007/BF01992163. PMID   8187784. S2CID   19358454.
  48. Dutta P, Mitra U, Dutta S, De A, Chatterjee MK, Bhattacharya SK (June 2001). "Ceftriaxone therapy in ciprofloxacin treatment failure typhoid fever in children". The Indian Journal of Medical Research. 113: 210–3. PMID   11816954.
  49. Коваленко АН, et al. (2011). "Особенности клиники, диагностики и лечения брюшного тифа у лиц молодого возраста". Voen.-meditsinskii Zhurnal. 332 (1): 33–39.
  50. Bhutta ZA, Khan IA, Molla AM (November 1994). "Therapy of multidrug-resistant typhoid fever with oral cefixime vs. intravenous ceftriaxone". The Pediatric Infectious Disease Journal. 13 (11): 990–4. doi:10.1097/00006454-199411000-00010. PMID   7845753.
  51. Cao XT, Kneen R, Nguyen TA, Truong DL, White NJ, Parry CM (March 1999). "A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. The Dong Nai Pediatric Center Typhoid Study Group". The Pediatric Infectious Disease Journal. 18 (3): 245–8. doi:10.1097/00006454-199903000-00007. PMID   10093945.
  52. Baron S et al.
  53. "Diarrhoeal Diseases". World Health Organization. February 2009. Archived from the original on November 2, 2011. Retrieved 2013-04-25.
  54. "WHO | Typhoid fever". www.who.int. Archived from the original on 2017-07-27. Retrieved 2017-08-10.
  55. Anyomih TK, Drake TM, Glasbey J, Fitzgerald JE, Ots R, et al. (GlobalSurg Collaborative) (October 2018). "Management and Outcomes Following Surgery for Gastrointestinal Typhoid: An International, Prospective, Multicentre Cohort Study". World Journal of Surgery. 42 (10): 3179–3188. doi:10.1007/s00268-018-4624-8. PMC   6132852 . PMID   29725797.
  56. Waddington CS, Darton TC, Pollard AJ (January 2014). "The challenge of enteric fever". The Journal of Infection. Hot Topics in Infection and Immunity in Children - Papers from the 10th annual IIC meeting, Oxford, UK, 2012. 68 (Suppl 1): S38-50. doi:10.1016/j.jinf.2013.09.013. PMID   24119827.
  57. 1 2 Gonzalez-Escobedo G, Marshall JM, Gunn JS (January 2011). "Chronic and acute infection of the gall bladder by Salmonella Typhi: understanding the carrier state". Nature Reviews. Microbiology. 9 (1): 9–14. doi:10.1038/nrmicro2490. PMC   3255095 . PMID   21113180.
  58. "Extensively Drug-Resistant Typhoid Fever in Pakistan – Watch – Level 1, Practice Usual Precautions – Travel Health Notices | Travelers' Health | CDC". wwwnc.cdc.gov. Retrieved 2020-04-21.
  59. Zaki SA, Karande S (May 2011). "Multidrug-resistant typhoid fever: a review". Journal of Infection in Developing Countries. 5 (05): 324–37. doi: 10.3855/jidc.1405 . PMID   21628808.
  60. Gibani MM, Britto C, Pollard AJ (October 2018). "Typhoid and paratyphoid fever: a call to action". Current Opinion in Infectious Diseases. 31 (5): 440–448. doi:10.1097/QCO.0000000000000479. PMC   6319573 . PMID   30138141.
  61. Cooke FJ, Wain J, Threlfall EJ (August 2006). "Fluoroquinolone resistance in Salmonella Typhi". BMJ. 333 (7563): 353–4. doi:10.1136/bmj.333.7563.353-b. PMC   1539082 . PMID   16902221.
  62. 1 2 "Typhoid Fever". World Health Organization. Archived from the original on 2011-11-02. Retrieved 2007-08-28.
  63. Crump JA, Luby SP, Mintz ED (May 2004). "The global burden of typhoid fever". Bulletin of the World Health Organization. 82 (5): 346–53. PMC   2622843 . PMID   15298225.
  64. Muyembe-Tamfum JJ, Veyi J, Kaswa M, Lunguya O, Verhaegen J, Boelaert M (January 2009). "An outbreak of peritonitis caused by multidrug-resistant Salmonella Typhi in Kinshasa, Democratic Republic of Congo". Travel Medicine and Infectious Disease. 7 (1): 40–3. doi:10.1016/j.tmaid.2008.12.006. PMID   19174300.
  65. Baddam R, Kumar N, Thong KL, Ngoi ST, Teh CS, Yap KP, et al. (July 2012). "Genetic fine structure of a Salmonella enterica serovar Typhi strain associated with the 2005 outbreak of typhoid fever in Kelantan, Malaysia". Journal of Bacteriology. 194 (13): 3565–6. doi:10.1128/jb.00581-12. PMC   3434757 . PMID   22689247.
  66. Yap KP, Teh CS, Baddam R, Chai LC, Kumar N, Avasthi TS, et al. (September 2012). "Insights from the genome sequence of a Salmonella enterica serovar Typhi strain associated with a sporadic case of typhoid fever in Malaysia". Journal of Bacteriology. 194 (18): 5124–5. doi:10.1128/jb.01062-12. PMC   3430317 . PMID   22933756.
  67. "WHO | A study of typhoid fever in five Asian countries: Disease burden and implications for controls". Archived from the original on July 14, 2008.
  68. Matano LM, Morris HG, Wood BM, Meredith TC, Walker S (December 2016). "Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening". Bioorganic & Medicinal Chemistry. 24 (24): 6307–6314. doi:10.1016/j.bmc.2016.08.003. PMC   5180449 . PMID   27594549.
  69. "Typhoid Fever" (PDF). Florida Department of Health. December 23, 2013.
  70. Heymann, David L., ed. (2008), Control of Communicable Diseases Manual , Washington, D.C.: American Public Health Association, pg 665. ISBN   978-0-87553-189-2.
  71. Levine MM, Black RE, Lanata C (December 1982). "Precise estimation of the numbers of chronic carriers of Salmonella typhi in Santiago, Chile, an endemic area". The Journal of Infectious Diseases. 146 (6): 724–6. doi:10.1093/infdis/146.6.724. PMID   7142746.
  72. Yap KP, Gan HM, Teh CS, Baddam R, Chai LC, Kumar N, et al. (November 2012). "Genome sequence and comparative pathogenomics analysis of a Salmonella enterica Serovar Typhi strain associated with a typhoid carrier in Malaysia". Journal of Bacteriology. 194 (21): 5970–1. doi:10.1128/jb.01416-12. PMC   3486090 . PMID   23045488.
  73. Yap KP, Gan HM, Teh CS, Chai LC, Thong KL (November 2014). "Comparative genomics of closely related Salmonella enterica serovar Typhi strains reveals genome dynamics and the acquisition of novel pathogenic elements". BMC Genomics. 15 (1): 1007. doi: 10.1186/1471-2164-15-1007 . PMC   4289253 . PMID   25412680.
  74. Crump JA, Sjölund-Karlsson M, Gordon MA, Parry CM (October 2015). "Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections". Clinical Microbiology Reviews. 28 (4): 901–37. doi:10.1128/CMR.00002-15. PMC   4503790 . PMID   26180063.
  75. Khan MI, Pach A, Khan GM, Bajracharya D, Sahastrabuddhe S, Bhutta W, et al. (June 2015). "Typhoid vaccine introduction: An evidence-based pilot implementation project in Nepal and Pakistan". Vaccine. 33 (Suppl 3): C62-7. doi:10.1016/j.vaccine.2015.03.087. PMID   25937612.
  76. "Extensively Drug-Resistant Typhoid Fever in Pakistan". Centers for Disease Control and Prevention. 30 September 2019.
  77. "Typhoid and paratyphoid fevers: Annual Epidemiological Report for 2017" (PDF). European Centre for Disease Prevention and Control. October 2020. Retrieved 20 July 2021.
  78. 1 2 3 Appiah GD, Chung A, Bentsi-Enchill AD, Kim S, Crump JA, Mogasale V, et al. (June 2020). "Typhoid Outbreaks, 1989–2018: Implications for Prevention and Control". The American Journal of Tropical Medicine and Hygiene. 102 (6): 1296–1305. doi:10.4269/ajtmh.19-0624. PMC   7253085 . PMID   32228795.
  79. 1 2 Papagrigorakis MJ, Yapijakis C, Synodinos PN, Baziotopoulou-Valavani E (May 2006). "DNA examination of ancient dental pulp incriminates typhoid fever as a probable cause of the Plague of Athens". International Journal of Infectious Diseases. 10 (3): 206–14. doi: 10.1016/j.ijid.2005.09.001 . PMID   16412683.
  80. Vågene Å, et al. (2018). "Salmonella enterica genomes from victims of a major sixteenth-century epidemic in Mexico". Nature Ecology & Evolution. 2 (3): 520–528. Bibcode:2018NatEE...2..520V. doi:10.1038/s41559-017-0446-6. PMID   29335577. S2CID   3358440.
  81. "Disease & Death in Early America: Tully Area Historical Society". tullyhistoricalsociety.org. Retrieved 2021-06-29.
  82. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 Adler R, Mara E (2016). Typhoid fever : a history. Jefferson, North Carolina: McFarland & Company. ISBN   978-0-7864-9781-2. OCLC   934938999.
  83. "Emsworth Oysters". Emsworth Business Association. 10 February 2019. Archived from the original on 3 February 2016.
  84. Bulstrode HT (1903). Dr. H. Timbrell Bulstrode's report to the Local Government Board upon alleged oyster-borne enteric fever and other illness following the mayoral banquets at Winchester and Southampton, and upon enteric fever occurring simultaneously elsewhere and also ascribed to oysters (Report). London: HMSO. p. 1.
  85. 1 2 3 4 5 6 7 8 "Typhoid Milkman". Remember Jamaica Plain?. 2007-11-05. Retrieved 2021-06-24.
  86. 1 2 3 Soper GA (October 1939). "The Curious Career of Typhoid Mary". Bulletin of the New York Academy of Medicine. 15 (10): 698–712. ISSN   0028-7091. PMC   1911442 . PMID   19312127.
  87. 1 2 3 "Short Wave: Typhoid Mary: Lessons From An Infamous Quarantine on Apple Podcasts". Apple Podcasts. Retrieved 2021-06-28.
  88. "Typhoid left city 'under siege'". 2008-06-26. Retrieved 2021-06-29.
  89. Lunguya O, Lejon V, Phoba MF, Bertrand S, Vanhoof R, Verhaegen J, et al. (2012-11-15). Ryan ET (ed.). "Salmonella typhi in the democratic republic of the congo: fluoroquinolone decreased susceptibility on the rise". PLOS Neglected Tropical Diseases. 6 (11): e1921. doi: 10.1371/journal.pntd.0001921 . PMC   3499407 . PMID   23166855.
  90. Platner SB, Ashby T (2002). A Topographical Dictionary of Ancient Rome. Oxford University Press. ISBN   9780199256495.
  91. Yapijakis C (2009). "Hippocrates of Kos, the father of clinical medicine, and Asclepiades of Bithynia, the father of molecular medicine. Review". In Vivo (Athens, Greece). 23 (4): 507–514. PMID   19567383. The Greek physician Antonius Musa notably cured the emperor Augustus of typhoid fever with cold baths
  92. Stachura J, Gałazka K (December 2003). "History and current status of Polish gastroenterological pathology". Journal of Physiology and Pharmacology. 54 (Suppl 3): 183–92. PMID   15075472.
  93. "Typhoid Fever Considered as a Problem of Scientific Medicine". JAMA: The Journal of the American Medical Association. 71 (10): 847. 1918-09-07. doi:10.1001/jama.1918.02600360063023. hdl: 2027/coo1.ark:/13960/t9d516735 . ISSN   0098-7484.
  94. Eberth CJ (1880). "Die Organismen in den Organen bei Typhus abdominalis" [Organisms in the [internal] organs in cases of Typhus abdominalis]. Archiv für pathologische Anatomie und Physiologie (in German). 81: 58–74.
  95. Eberth CJ (1881). "Neue Untersuchungen über den Bacillus des Abdominaltyphus" [New investigations into the bacilli of abdominal typhoid]. Archiv für pathologische Anatomie und Physiologie (in German). 83: 486–501.
  96. Eberth's findings were verified by Robert Koch Koch R (1881). "Zur Untersuchung von pathogenen Organismen" [On the investigation of pathogenic organisms]. Mitteilungen aus dem Kaiserlichen Gesundheitsamte (in German). 1: 1–49. Archived from the original on 2017-04-23.
  97. Gaffky G (1884). "Zur aetiologie des abdominaltyphus" [On the etiology of abdominal typhus]. Mitteillungen aus dem Kaiserlichen Gesundheitsamt (in German). 2: 372–420. Archived from the original on 2017-04-23.
  98. Wertheim HF, Horby P, Woodall JP (2012). Atlas of Human Infectious Diseases (1st ed.). New York, NY: John Wiley & Sons. ISBN   978-1-4443-5467-6. OCLC   897547171.
  99. "Typhoid Epidemic at Maidstone". Journal of the Sanitary Institute. 18: 388. October 1897.
  100. "A miracle for public health?" . Retrieved 2012-12-17.
  101. Leal JL (1909). "The Sterilization Plant of the Jersey City Water Supply Company at Boonton, N.J.". Proceedings American Water Works Association. pp. 100–9.
  102. Fuller GW (1909). "Description of the Process and Plant of the Jersey City Water Supply Company for the Sterilization of the Water of the Boonton Reservoir.". Proceedings American Water Works Association. pp. 110–34.
  103. Von Hoffman A (1996). Local attachments : the making of an American urban neighborhood, 1850 to 1920. Johns Hopkins University Press. OCLC   1036707621.
  104. "Nova: The Most Dangerous Woman in America". PBS . Archived from the original on 2010-04-26.
  105. Klein C. "10 Things You May Not Know About 'Typhoid Mary'". HISTORY. Retrieved 2021-06-28.
  106. 1 2 3 4 5 6 7 8 Sears HJ, Garhart RW, Mack DW (October 1924). "A Milk Borne Epidemic of Typhoid Fever Traced to a Urinary Carrier". American Journal of Public Health. 14 (10): 848–54. doi:10.2105/ajph.14.10.848. PMC   1355026 . PMID   18011334.
  107. 1 2 3 4 "Typhoid Carriers and Their Treatment". Journal of the American Medical Association. 100 (23): 1866. 1933-06-10. doi:10.1001/jama.1933.02740230044012. ISSN   0002-9955.
  108. Stanaway JD, Reiner RC, Blacker BF, Goldberg EM, Khalil IA, Troeger CE, et al. (April 2019). "The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017". The Lancet. Infectious Diseases. 19 (4): 369–381. doi:10.1016/S1473-3099(18)30685-6. PMC   6437314 . PMID   30792131.
  109. 1 2 3 4 "Acute Communicable Disease Control Manual (B-73): Typhoid Fever Carrier" (PDF). Los Angeles Department of Public Health. June 2018. Retrieved June 27, 2021.
  110. Prouty AM, Schwesinger WH, Gunn JS (May 2002). "Biofilm formation and interaction with the surfaces of gallstones by Salmonella spp". Infection and Immunity. 70 (5): 2640–9. doi:10.1128/iai.70.5.2640-2649.2002. PMC   127943 . PMID   11953406.
  111. 1 2 Monack DM, Bouley DM, Falkow S (January 2004). "Salmonella typhimurium persists within macrophages in the mesenteric lymph nodes of chronically infected Nramp1+/+ mice and can be reactivated by IFNgamma neutralization". The Journal of Experimental Medicine. 199 (2): 231–41. doi:10.1084/jem.20031319. PMC   2211772 . PMID   14734525.
  112. Lawley TD, Bouley DM, Hoy YE, Gerke C, Relman DA, Monack DM (January 2008). "Host transmission of Salmonella enterica serovar Typhimurium is controlled by virulence factors and indigenous intestinal microbiota". Infection and Immunity. 76 (1): 403–16. doi:10.1128/iai.01189-07. PMC   2223630 . PMID   17967858.
  113. "Sir Almroth Edward Wright". Encyclopædia Britannica. Archived from the original on 2013-11-11.
  114. Wright AE, Douglas SR (1904-01-31). "An experimental investigation of the rôle of the blood fluids in connection with phagocytosis". Proceedings of the Royal Society of London. 72 (477–486): 357–370. doi:10.1098/rspl.1903.0062. ISSN   0370-1662. S2CID   84388525.
  115. "Library and Archive Catalogue". Royal Society. Retrieved 1 November 2010.[ permanent dead link ]
  116. "Medical lessons from World War I underscore need to keep developing antimicrobial drugs". MinnPost. 2014-11-11. Archived from the original on 30 January 2016. Retrieved 8 September 2017.
  117. USAMRMC: 50 Years of Dedication to the Warfighter 1958–2008 (PDF). U.S. Army Medical Research & Material Command (2008). 2008. p. 5. ASIN   B003WYKJNY. Archived from the original (PDF) on 2013-02-14. Retrieved 2013-03-27.
  118. Felix A, Pitt RM (July 1934). "A New Antigen of B. Typhosus". The Lancet. 224 (5787): 186–191. doi:10.1016/S0140-6736(00)44360-6.
  119. Craigie J (1957-11-01). "Arthur Felix, 1887–1956". Biographical Memoirs of Fellows of the Royal Society. 3: 53–79. doi:10.1098/rsbm.1957.0005. S2CID   72753150.
  120. "Typhoid Fever". Center for Emerging and Re-emerging Infectious Diseases. University of Washington. Archived from the original on 2019-12-08. Retrieved 2019-12-08.
  121. "TYPHOID OR DRAIN FEVER, AND HOW TO PREVENT ITS SPREADING". The Warwick Examiner and Times . 6 April 1878. Retrieved 13 April 2020.
  122. Darby E (1983). The cult of the Prince Consort. Nicola Smith. New Haven: Yale University Press. ISBN   0-300-03015-0. OCLC   10432279.
  123. Matthew HC (September 2004). "Edward VII (1841–1910)". Oxford Dictionary of National Biography (online ed.). Oxford University Press (published May 2006). doi:10.1093/ref:odnb/32975. Archived from the original on 2016-03-02.(Subscription or UK public library membership required.)
  124. "Nicholas II - At the Court of the Last Tsar - Chapter 1, Part 2, The Empress Alexandra". www.alexanderpalace.org. Retrieved 2021-06-21.
  125. "Hoogleraar heeft aanwijzingen voor abortus bij Wilhelmina: 'Monarchie hing aan zijden draadje' (Professor has indication for abortion Wilhelmina: Monarchy was hanging by a thread)". RTL Nieuws (in Dutch). 2023-04-19.
  126. Trudy Dehue. "Egg Foetus Baby, A New History of Pregnancy". Dutch foundation for literature. Archived from the original on 2024-03-17. Retrieved 2023-12-06.
  127. Dennis B (2011-09-29). "Willie Lincoln's death: A private agony for a president facing a nation of pain". The Washington Post. ISSN   0190-8286. Archived from the original on 2017-04-01. Retrieved 2017-03-12.
  128. "Maldiçãp, febre e alucinações: a melancólica morte de Leopoldina de Bragança". aventurasnahistoria.uol.com.br. June 7, 2020. Retrieved February 3, 2022.
  129. "A History of Stanford". Stanford University. Retrieved 4 July 2018.
  130. Ruggles E (1944). Gerard Manley Hopkins: A Life . Norton.
  131. Scott BF (23 September 1910). "Scott, Henry James Herbert (1858–1910)". Australian Dictionary of Biography – Henry James Herbert Scott. National Centre of Biography, Australian National University. Archived from the original on 2011-02-21.
  132. "Straw for Silence". The Spectator . Vol. 203. F.C. Westley. 1959. ISSN   0038-6952. OCLC   1766325.
  133. Hakaru Hashimoto#Biography

Further reading